Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
SOURCE Research and Markets
DUBLIN, Feb. 12, 2014 /PRNewswire/ --Research and Markets (http://www.researchandmarkets.com/research/cn9qz8/nuclear_medicine) has announced the addition of the "Concise Analysis of the International Nuclear Medicine Market & Radiopharmaceuticals - Trends & Forecast to 2017" report to their offering.
Radiopharmaceuticals are drugs that contain radionuclide-emitting ionizing radiation and are used for disease diagnosis and treatment. They provide increased understanding of diseases as they not only give anatomical but also functional information about the organ. Radiopharmaceuticals are also used in the nuclear imaging field as tracers. They are mostly used for diagnosis with the use of gamma cameras for imaging techniques such as in SPECT and PET. Radioisotopes are used in medical applications with more than 90% share. Medical application is driven by the increasing patient population and new and effective radioisotopes. The most commonly used isotopes for diagnosis are Tc-99m and Tl-201 for SPECT and F-18 for PET.
The radiopharmaceuticals market is broadly classified into two segments, namely, diagnostic and therapeutic; the former dominated with about 85% share in 2012. Radioisotopes in the diagnostic market are categorized as SPECT and PET. Technetium 99m (Tc-99m) dominated the SPECT radioisotope market in 2012, followed by thallium-201 (Tl-201), gallium-;67 (Ga-67) and iodine-123 (I-123). SPECT is majorly used in the diagnosis of cardiac diseases; it is poised to grow at a stable CAGR from 2012 to 2017. The PET radioisotopes market is dominated by fluorine-18 (F-18), followed by rubidium-82 (Rb-82) and poised to grow at a CAGR of more than 10% in the near future.
Segments in the therapeutic market are beta emitters, brachytherapy isotopes, and alpha emitters. Quantitative information about alpha emitters is not conclusive, as they have not been commercialized; recent clinical studies have, however, showcased immense potential of alpha isotopes in therapies. Beta emitters contribute the highest to the therapy market, dominated by iodine-131(I-153), which is poised to grow at a decent CAGR of about 5.0% from 2012 to 2017. The market is driven by its applications for thyroid cancer, hyperthyroidism, and non-Hodgkin-s lymphoma. Significant isotopes in the brachytherapy market are cesium-131(Cs-131), iodine-125 (I-125), palladium-103 (Pd-103), and iridium-192 (Ir-192). North America is the major market for brachytherapy in terms of market share, followed by Europe. However, it is showing slow growth due to reimbursement issues.
Key Topics Covered:
2 Executive Summary
3 Market Overview
4 Global Radiopharmaceuticals Market, By Value
5 Global Radiopharmaceuticals Market, By Procedural Volume
6 Radiopharmaceuticals Market, By Application/Indication
7 Enriched Stable Isotopes Market
8 Geographic Analysis
9 Competitive Landscape
10 Company Profiles
- Bracco Imaging SPA
- Cambridge Isotope Laboratories, Inc
- Cardinal Health, Inc
- Covidien, Plc
- Fujifilm Holdings Corporation
- Ge Healthcare (Subsidiary Of General Electric Company)
- Iba Group
- Isotec, Inc (Sigma-Aldrich)
- Lantheus Medical Imaging, Inc
- Nordion, Inc
- Ntp Radioisotopes (PTY), Ltd
- Petnet Solutions, Inc (A Subsidiary Of Siemens Medical Solutions Usa, Inc)
- Rotem Industries, Ltd, Inc
- Taiyo Nippon Sanso Corporation
- Urenco Limited
Institutes Mentioned in the Report
- Australian Nuclear Association And Technology Organization (Ansto)
- Board Of Radiation And Isotope Technology (Brit)
- Institute Of Atomic Energy Polatom Radioisotope Centre
- Institute Of Isotopes Co, Ltd
- Institute Of Radioelement (IRE)
For more information visit http://www.researchandmarkets.com/research/cn9qz8/nuclear_medicine
Media Contact: Laura Wood , +353-1-481-1716, firstname.lastname@example.org
©2012 PR Newswire. All Rights Reserved.